

AD-A218 936

AD _____

CONTRACT NO: DAMD17-87-C-7004

TITLE: THE MECHANISM OF ACTION OF RIBAVIRIN ON BUNYAVIRUS
INFECTED CELLS

PRINCIPAL INVESTIGATOR: Jean L. Patterson

CONTRACTING ORGANIZATION: Children's Hospital Corporation
300 Longwood Avenue
Boston, MA 02115

REPORT DATE: March 3, 1989

TYPE OF REPORT: Midterm Report

PREPARED FOR: U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21701-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The findings in this report are not to be construed as an
official Department of the Army position unless so designated by
other authorized documents.

90 03 02 057

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1a. REPORT SECURITY CLASSIFICATION Unclassified			1b. RESTRICTIVE MARKINGS		
2a. SECURITY CLASSIFICATION AUTHORITY			3. DISTRIBUTION / AVAILABILITY OF REPORT Approved for public release; distribution unlimited		
2b. DECLASSIFICATION / DOWNGRADING SCHEDULE			4. PERFORMING ORGANIZATION REPORT NUMBER(S)		
6a. NAME OF PERFORMING ORGANIZATION Children's Hospital Corporation			6b. OFFICE SYMBOL (If applicable)		7a. NAME OF MONITORING ORGANIZATION
6c. ADDRESS (City, State, and ZIP Code) 300 Longwood Avenue Boston, MA 02115			7b. ADDRESS (City, State, and ZIP Code)		
8a. NAME OF FUNDING / SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command		8b. OFFICE SYMBOL (If applicable)		9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER Contract No. DAMD17-87-C-7004	
8c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012		10. SOURCE OF FUNDING NUMBERS		10. SOURCE OF FUNDING NUMBERS	
		PROGRAM ELEMENT NO. 62787A	PROJECT NO. 3M1- 62787A871	TASK NO. AH	WORK UNIT ACCESSION NO. 397
11. TITLE (Include Security Classification) THE MECHANISM OF ACTION OF RIBAVIRIN ON BUNYAVIRUS INFECTED CELLS					
12. PERSONAL AUTHOR(S) Jean L. Patterson					
13a. TYPE OF REPORT Midterm Report		13b. TIME COVERED FROM 8/1/87 TO 1/31/89		14. DATE OF REPORT (Year, Month, Day) 1989 March 3	
15. PAGE COUNT 13					
16. SUPPLEMENTARY NOTATION					
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary, and identify by block number)		
FIELD	GROUP	SUB-GROUP			
06	13		Ribavirin, Bunyavirus, Antiviral, Mechanism of action,		
06	01		Cell Cultures, RA I, BD, BIOCHEMISTRY, CELLS (B10-074)		
19. ABSTRACT (Continue on reverse if necessary, and identify by block number)					
<p>Ribavirin (1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) or Virazole is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. The drug was approved by the Food and Drug Administration in 1986 for aerosol use in infants with serious infections due to respiratory syncytial virus (RS). Ribavirin is and has been under clinical investigation against a variety of viral illness, including those due to influenza virus, Lassa fever, Korean hemorrhagic fever with renal syndrome (KHFS) and Human immunodeficiency virus (HIV). There has been a great deal of clinical interest in utilizing ribavirin for HIV infections. It has been reported to slow the development of AIDS in HIV infected patients (McCormick et al., 1984). We describe here the reported mechanisms of action of this newly licensed drug.</p>					
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT <input type="checkbox"/> UNCLASSIFIED/UNLIMITED <input checked="" type="checkbox"/> SAME AS RPT <input type="checkbox"/> DTIC USERS			21. ABSTRACT SECURITY CLASSIFICATION Unclassified		
22a. NAME OF RESPONSIBLE INDIVIDUAL Mrs. Virginia M. Miller			22b. TELEPHONE (Include Area Code) (301) 663-7325		22c. OFFICE SYMBOL SGRD-RMI-S

Ribavirin (1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) or Virazole is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. The drug was approved by the Food and Drug Administration in 1986 for aerosol use in infants with serious infections due to respiratory syncytial virus (RS). Ribavirin is and has been under clinical investigation against a variety of viral illness, including those due to influenza virus, Lassa fever, Korean hemorrhagic fever with renal syndrome (KHFS) and Human immunodeficiency virus (HIV). The drug possesses inhibitory activity against a broad spectrum of viral pathogens, including both DNA and RNA viruses (Sidwell et al., 1972), intrinsically suggesting a vast clinical potential that has yet to be realized.

There has been a great deal of clinical interest in utilizing ribavirin for HIV infections. It has been reported to slow the development of AIDS in HIV infected patients (McCormick et al., 1984). The mechanism for the interference of ribavirin on HIV is as yet not understood. Recently Vogt et al (1987) reported that this drug was antagonistic with AZT in HIV infected cells. They hypothesized that since both drugs work in some part as a triphosphate that there is competition for cellular kinases.

Several theories regarding the molecular mode of action of ribavirin have been proposed. One hypothesis states that the drug leads to decreased intracellular pools of GTP,



Codes	
Dist	Special
A-1	

indirectly suppressing viral nucleic acid synthesis (Malinoski and Stollar, 1981 and Streeter et al., 1973). Another hypothesis proposes that ribavirin therapy of viral-infected cells results in the synthesis of RNA with abnormal or absent 5' cap structures, which in turn leads to inefficient translation of viral transcripts (Goswami et al., 1979). A third hypothesis states that the drug has a direct suppressive effect on viral polymerase activities. Experimentally it has been difficult to determine the primary mechanism of action because none of these hypotheses are mutually exclusive, and indeed, they may indicate that ribavirin acts in a complex, multiple site fashion. It is also important to note that ribavirin, unlike all other drugs whose structures resemble nucleoside analogues, has a modified base. Antiviral agents, notably AZT, have modified sugars and generally are terminators of growing nucleic acid chains. Their major mode of action was relatively simple to determine.

Ribavirin was initially described as closely resembling guanosine in structure (Prusiner and Sundaralingam, 1973) and it was found that when cells were treated with this drug pools of GTP were diminished (Smith, 1984). Early after the development of this drug, ribavirin-5'-monophosphate was shown to be a potent inhibitor of IMP dehydrogenase activity (Malinoski and Stollar, 1981). The hypothesis was made that the remaining cellular and viral enzymes were thought to compete for the depleted concentration of GTP. The major

evidence against this being the primary mode of antiviral action is that other compounds notably, the 1,4,5-triazole derivative of ribavirin which deplete GTP pools, have no antiviral activity (Smith, 1984). Again, it is important to note that no mechanism excludes another, all could work and thereby enhance each other's effectiveness.

The hypothesis that ribavirin exerts its antiviral effect by blocking capping comes from early work with vaccinia virus. Katz et al (1976) reported that ribavirin inhibited vaccinia virus growth in BSC I cells. Fifty ug/ml of virazole inhibited virus growth more than ten-fold, the effect, however, was not linear, because 25 ug/ml caused only a two-fold decrease. Equimolar concentrations of guanosine added to cells resulted in loss of the inhibitory effect. In an assay measuring the appearance of viral particles ribavirin interfered dramatically. Their final conclusion was that ribavirin interfered with DNA synthesis in some unknown fashion. More recently Goswami et al (1982) have used purified vaccinia virus capping enzymes and shown that ribavirin 5'-triphosphate was an effective inhibitor of the viral mRNA (guanine-7) methyltransferase, indeed by their kinetic analysis it appeared to be a direct competitive inhibitor. Canonico et al (1980) reported that when examining mRNA from Eastern equine encephalitis virus infected cells that the transcripts appeared to have lost their cap structure. In another reported set of experiments

(Toltzis and Huang, 1986) in which the effects of ribavirin on vesicular stomatitis virus (VSV) grown in Chinese hamster ovary cells were examined, it was indicated that the drug leads to the synthesis of inefficiently translated viral mRNA. There was only a little demonstrable effect on viral primary transcription, lending support to the hypothesis that the drug alters RNA cap structures.

The problem with these and other experiments dealing with translational efficiencies and capping is that it is not clear that a cap is an absolute requirement for translation. Polio virus which does not have a cap on its mRNA translates adequately. Ironically, we have learned a great deal about the function, or lack thereof, of cap structures from this virus (see Ehrenfeld, 1982). More importantly, in vitro translation of mRNAs is notoriously unfaithful to the situation inside the infected cell. Rabbit reticulocyte lysate, in particular, will initiate internally on a message producing truncated proteins where none exist inside the cell. Unfortunately, the assay to accurately measure translational efficiency is yet to be developed.

The idea that ribavirin may directly affect polymerases has been reported previously for other viruses, notably influenza virus (Wray et al., 1985). Work in our lab has indicated that the structural similarity of ribavirin may include all of the natural nucleoside triphosphates.

Results of our experiments in which the effects of phosphorylated ribavirin compounds on an in vitro VSV polymerase assay were examined, indicated that the drug does indeed possess a significant direct suppressive effect on viral polymerase (Toltzis et al., 1988). In fact all three phosphorylated species inhibited VSV transcription. The mono- and diphosphorylated forms of the drug possessed approximately two to three times the inhibitory activity as the triphosphorylated form. Transcripts synthesized in the presence of the drug were full-length. Inhibition by ribavirin 5'-diphosphate could be reversed by the addition of UTP, CTP and GTP. While the addition of GDP to the reaction did not reverse inhibition. Nearest neighbor analysis supported the notion that none of the phosphorylated forms were incorporated into the growing chain of RNA. Surprisingly, in contrast to the viral mRNA synthesized in infected cells in the presence of ribavirin transcripts synthesized in vitro (in the test tube) in the presence 5' mono-, di-, and triphosphorylated forms of the drug translated with equal efficiencies under the test conditions. This results either suggest a contradiction to the theory that ribavirin affects cap structures and interferes with translation, or that the in vitro RNA synthesis system cannot mimic the cellular machinery accurately.

Our initial observation that besides the triphosphorylated form both the mono- and di-phosphorylated

forms of the drug were active against the VSV replicase was surprising. It has been shown previously that all nucleoside analogs inhibit viral polymerases in the triphosphorylated form (Eriksson et al., 1977, Furman et al., 1984). We have used enzyme kinetic procedures and product analysis to further investigate the mechanism of action of ribavirin. When analyzed by double-reciprocal plots both RDP and RTP gave similar patterns of inhibition, although the K_m values of the nucleoside triphosphates in the presence of the different drugs are not the same (Fernandez-Larsson et al., 1989). Both of the phosphorylated forms of ribavirin compete directly with all four of the nucleoside triphosphates, suggesting that they are acting on the polymerase in a similar fashion. Because there appears to be no incorporation of ribavirin into the growing nucleic acid chain and because the transcripts synthesized appear full length in the presence of both drugs it was our initial hypothesis that RDP and RTP were blocking polymerase initiation at the 3' terminus of the genome.

We then studied purified in vitro transcription products synthesized in the presence and absence of phosphorylated ribavirin compounds to determine the effect of these drugs on leader RNA and mRNA synthesis and to further characterize the observations on enzyme kinetics. VSV leader RNA is a 47 nucleotide noncapped and nonpolyadenylated RNA transcript which is the first RNA synthesized after the polymerase begins transcription, it is complimentary to the exact 3'

end of the negative stranded RNA genome. The next transcript synthesized is the nucleocapsid (N) mRNA. It is both capped and polyadenylated. We found that the inhibition of leader synthesis was similar to the inhibition of N mRNA synthesis, since the ratios of these two RNA transcripts did not appear to change with the addition of RDP or RTP to the transcription reaction. The results suggest that the inhibitory effect of ribavirin on the polymerase occurs at the level of initiation of primary transcription, when the transcriptase enters the 3' end of the genome. Later, using the same type of analysis we were able to show that a VSV mutant had an altered ATP function. Kinetic analysis clearly showed that the direct competitive effect of RDP or RTP was different in this mutant (Fernandez-Larsson and Patterson, 1989). The altered ATP function observed in the kinetic analysis is compatible with the argument for an additional ATP-binding site on the polymerase complex. In this mutant RTP and RDP seemed to interact in a different manner with the ATP binding sites than they do with wild-type VSV.

In another viral system, reovirus, researchers reported that 12.5 μ M of ribavirin inhibits all stages of viral replication (Rankin et al., 1989). Reovirus is a dsRNA virus. When RTP was tested on an in vitro transcription reaction utilizing the dsRNA genomes as template, both elongation and initiation of plus stranded mRNAs were inhibited. There was no effect on cap formation and/or

methylation. These results are quite similar to the VSV situation where no effect on apparent in vitro translatability could be found when mRNA was synthesized in vitro. These authors have suggested a model that supports RTP binding to a catalytic site on the transcriptase, again similar to what we have seen with VSV.

Our data and others have suggested that ribavirin has an effect on the initial steps of transcription by RNA-dependent RNA polymerases and that this effect may be mediated by several phosphorylated forms. One of the reasons that the antiviral activity of ribavirin maybe so formidable to pin down is that the inhibition of polymerases, without chain termination, is more difficult to assess. However, if indeed primary transcription is affected, direct linear effects of the drug on later stages in viral replication and assembly are difficult to ascertain as any deregulation of the system at the mRNA level is presumably amplified at all levels of viral progeny production. These small effects on primary transcription, may be enough to produce the entire antiviral activity seen, with respect to diminished viral titres. Unfortunately there is little information on how ribavirin may interfere with DNA viruses.

All antiviral compounds must be evaluated recognizing that by the time "self-limiting" diseases are recognized

most replication and viral progeny production is accomplished. The damage is done, so to speak. It is not fair to compare these compounds with antibacteriocidal agents. The reality is that most of the effective antivirals will only work on chronic infections. Nevertheless, as the development of antiviral compounds grows, we need to adequately prepare ourselves to determine, primarily via rapid viral diagnostics, which virus is the agent and the length of the viral infection.

Ribavirin remains an important potential agent in the treatment of a broad spectrum of serious viral illnesses encountered worldwide and may serve as a model for similar, more effective agents in the future. Definition of its molecular activity will be vital to the development of its use and the use of similar agents.

Canonico P, Little JS, Jahling PB, Stephen E. Curr Chemother Proc 11thICC & 19th ICA pp. 1980;1370-1372

Eriksson BE, Helgstrand E, Johnson A, Larsson A, Misiorny JO, Noren T, Philipson K, Stenberg K, Stening G, Stridh S and Oberg B. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 1977;11:946-951.

Fernandez-Larsson, R, O'Connell K, Koumens, E, and Patterson JL. Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction. Antimicro Agents and Chemother 1989;33:1668-1673.

Fernandez-Larsson, R, and Patterson JL. Altered ATP function of vesicular stomatitis virus mutant detected by kinetic analysis of the transcriptase using phosphorylated ribavirin. J gen Virol 1989;70:2791-2797.

Ferrara EQ, Oishi JS, Wannamacher Jr. RW and Stephen FL. Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys. Antimicrob Agents and Chemother 1981;19:1042-1049.

Furman PA, St. Clair MH, and Spector T. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J Biol Chem 1984;259:9575-9579.

Goswami BB, Borek and Sharma OK. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA Biochem Biophys Res Commun 1979;89:830-836.

Katz E, Margalith E. and Winer B. Inhibition of Vaccinia Virus Growth by the nucleoside analogue 1-B-D-riboviranosyl-1,2,4-Triazole-3-Carboxamide (Virazole, Ribavirin). J gen Virol 1976;32:327-330.

Lee HW, Lee PW, Baek LJ, Song CK, Seong JW. Intraspecific transmission of Hantaan virus, etiologic agent of Korean hemorrhagic fever in the rodent Apodemus agrarius. Am J Trop Med Hyg 1981;30:1106-1112.

Leppert M, Rittenhous L, Perrault J, Summers DF and Kolakofsky D. Plus and minus strand leader RNAs in negative strand virus-infected cells Cell 1979;18:735-747.

Malinoski F and Stollar F. Inhibitors of IMP dehydrogenase prevent Sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology 1981;110:281-291.

McCormick JB, Getchell JP, Mitchell SW, Hicks HR. Lancet

1984;II:1367.

Prusiner P and Sundaralingam M. Structure of antiviral agents. *Nature New Biol* 1973;244:116

Rankin JT, Eppes SB, Antczak JB, and Joklik WK. 1989. Studies on the mechanism of the antiviral activity of ribavirin against Reovirus. *Virology* 1989;168:147-158.

Sidwell TK, RW, JN Huffman, GP Khard, LB Allen, JT Witkowski and Robins RK. Broad spectrum antiviral activity of virazole: 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboximide. *Science* 1972;177:705-706.

Sidwell RW, Huffman JH, Barnett BB and Pifat DY. In vitro phlebovirus inhibition by ribavirin. *Antimicro Agents Chemother* 1988;32:331-336.

Smith RA. Background and mechanisms of action of ribavirin. p. 1-18. In RA Smith, V. Knight, and JAD Smith (ed). *Clinical applications of actions of ribavirin*. Academic Press Inc. New York. 1984.

Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ. Robins RK, and Simon LN. Mechanism of action of 1-B-D-ribovuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. *Proc Natl Acad Sci USA* 1973;70:1174-1178.

Toltzis P and Huang AS. 1986. Effect of ribavirin on macromolecular synthesis in vesicular stomatitis virus-infected cells. *Antimicrob Agents Chemother* 1986;15:747-753.

Toltzis P, O'Connell K and Patterson JL. 1988. Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription. *Antimicrob Agents Chemother* 1988;32:492-497.

Vogt MW, Harstshorn KL, Furman PA, Chou T-C, Fyfe JA, Coleman LA, Crumpacker C, Schooley RT and Hirsch MS. Ribavirin antagonizes the effect of azidothymidine on HIV replication. *Science* 1987;235: 1376-1379.

Wray SK, Gilbert BF, and Knight V. Effect of ribavirin triphosphate on primed generation and elongation during virus transcription in vitro. *Antiviral Res* 1985; 5:39-48.